Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.52 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209838 | 1.00 | GLS (0.52) | GLSKDM4ABRD4CREBBPGRM2 | |
| SCHEMBL25372210 | 0.88 | GLS (0.43) | GLSKDM4ABRD4CREBBPGRM2 | |
| SCHEMBL6258024 | 0.87 | HDAC1 (0.53) | GLSL3MBTL1HDAC1 | |
| SCHEMBL698405 | 0.86 | NQO2 (0.49) | GLSNAMPTCA1ATMCYP3A4 | |
| SCHEMBL6243284 | 0.86 | HDAC1 (0.51) | GLSKDM4ABRD4CREBBPGRM2 | |
| SCHEMBL26508626 | 0.86 | HDAC1 (0.56) | GLSKDM4ABRD4CREBBPGRM2 | |
| SCHEMBL13181773 | 0.85 | GLS (0.47) | GLSKDM4ABRD4CREBBPGRM2 | |
| SCHEMBL30580198 | 0.85 | GLS (0.47) | GLSKDM4ABRD4CREBBPGRM2 | |
| SCHEMBL8985043 | 0.85 | MMP1 (0.51) | GLSKDM4ABRD4CREBBPCA12 | |
| SCHEMBL25370290 | 0.85 | GLS (0.47) | GLSKDM4ABRD4CREBBPGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | CELLARITY, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| WO-2025096981-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | CELLARITY, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | GLS 443/4885KDM4A 4649/4885BRD4 4545/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | GLS 2543/4885KDM4A 2160/4885BRD4 473/4885 |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | GLS 443/4885KDM4A 4649/4885BRD4 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.